A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

May 8, 2015

Primary Completion Date

January 18, 2017

Study Completion Date

June 19, 2017

Conditions
Non-Alcoholic Steatohepatitis
Interventions
DRUG

BMS-986036

DRUG

BMS-986036

DRUG

Placebo

Trial Locations (17)

15213

Upmc Center For Liver Diseases, Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

23502

Digestive and Liver Disease Specialists, Norfolk

27710

Duke University Medical Center, Durham

28204

Carolinas Healthcare System, Charlotte

37211

Quality Medical Research PLLC, Nashville

38138

Gastro One, Germantown

46202

Indiana University Health - University Hospital, Indianapolis

63104

Saint Louis University, St Louis

76012

Texas Clinical Research Institute, LLC, Arlington

77030

St. Luke'S Episcopal Hospital - Baylor College Of Medicine, Houston

78215

Texas Liver Institute, San Antonio

78234

Brooke Army Medical Center, Fort Sam Houston

92103

University Of California, San Diego, San Diego

92377

Inland Empire Liver Foundation, Rialto

27599-7584

Unc Hospitals And Clinics, Chapel Hill

23298-0341

Virginia Commonwealth University, Richmond

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY